价格降超50% 长效生长激素益佩生 纳入医保

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security of China have jointly issued the new National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025), which includes the long-acting growth hormone, Yipeisheng, developed by Tebao Biologics [1] - Approximately 7 million children in China suffer from growth hormone deficiency, and the number of cases is on the rise, highlighting the critical need for effective treatment options [1] - The inclusion of Yipeisheng in the new drug list is expected to alleviate the challenges faced in the pediatric growth hormone treatment sector, such as adherence issues with daily injections of short-acting formulations and the high cost and limited options of long-acting drugs [1] - The new drug list will take effect on January 1, 2026 [1] Pricing and Accessibility - Following its inclusion in the new drug list, the price of Yipeisheng will decrease by over 50%, significantly reducing the financial burden on patients and improving treatment accessibility [2]